Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
企業コードBVS
会社名Bioventus Inc
上場日Feb 11, 2021
最高経営責任者「CEO」Claypoole (Robert E)
従業員数930
証券種類Ordinary Share
決算期末Feb 11
本社所在地4721 Emperor Boulevard, Suite 100
都市DURHAM
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号27703
電話番号19194746700
ウェブサイトhttps://www.bioventus.com/
企業コードBVS
上場日Feb 11, 2021
最高経営責任者「CEO」Claypoole (Robert E)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし